A treatment and a condition, followed through the public trial records. Not medical advice. How a status is set
Phase 1 trial. Early trial in people, checking safety. As of 19 Nov 2026, from 1 registered trial.
Put together by software, not yet checked by a person
Why this status
22 Aug 2025: Trial registered, NCT07137416
6 Oct 2026: Trial started, NCT07137416
The trials
NCT07137416: Testing the Safety of the Combination of Anti-Cancer Drugs CX-5461 (Pidnarulex) and Trastuzumab Deruxtecan (T-DXd) for Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Solid Tumors and Breast Cancer
State
Under way
Phase
Phase 1
People
36 planned
Started
6 Oct 2026
Primary completion
10 Jan 2028
Arms
Treatment (Pidnarulex, T-DXd)
Results
None posted
22 Aug 2025: Trial registered
6 Oct 2026: Trial started
How the status changed
19 Nov 2026: First set: Phase 1 trial
Registries searched: ClinicalTrials.gov, through 17 Nov 2026.